Medicare explains how it will choose drugs for negotiation

Medicarelaidoutinthegreatestdetailyethowitwillchoosewhichdrugpricesitwillnegotiateinitsbrand-newprog AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real




fashion

author:knowledge    Page View:16235
An FDA sign — health policy coverage from STAT
Sarah Silbiger/Getty Images

WASHINGTON — There’s about to be a new acronym in town.

The Food and Drug Administration is in the final stages of cementing sweeping changes to the Office of Regulatory Affairs, which oversees inspections and compliance for all its regulated products, according to three people familiar with the planning.

advertisement

That overhaul includes a new name: Meet the Office of Inspections and Investigations.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In